Demanding that a patient's need is "exceptional" is irrational and should be abandoned 
Narcolepsy affects around 4 in 10 000 people, making it about one quarter as common as multiple sclerosis in the United Kingdom.
1 Its cardinal features are excessive daytime sleepiness causing frequent, irresistible naps; cataplexy, leading to collapse, embarrassment, and sometimes injury; and marked disturbance of nocturnal sleep. It is usually due to a specific deficiency of the hypothalamic neurotransmitter hypocretin and most often starts in the teens, probably as the result of an autoimmune process. Narcolepsy is far more than an occasional dose of sleepiness: it is a lifelong, pervasive, and potentially disabling disorder with a similar effect on quality of life to treatment resistant epilepsy. 2 While potentially disabling, it is also highly treatable. 3 A combination of stimulants (typically modafinil or dexamfetamine or both) and antidepressants (to reduce cataplexy) improves symptoms appreciably in most patients. But treatment response may be partial; contraindications or side effects can prevent their use; and none of these drugs deals with the third cardinal symptom of narcolepsy, which is sometimes the most distressing-the fragmentation of nocturnal sleep.
Enter sodium oxybate (Xyrem) or γ-hydroxybutyrate (GHB), an agonist at GABA B (γ-aminobutyric acid type B) and GHB receptors. 4 It has a chequered history. Following a period of use as a hypnotic and anaesthetic, GHB acquired a louche reputation as a date rape and recreational drug. More recently a series of trials have shown its efficacy in treating narcolepsy: given at night in two doses 3-4 hours apart, sodium oxybate consolidates nocturnal sleep, reduces excessive daytime sleepiness, and often abolishes cataplexy. Its potential to cause respiratory depression in overdose and substantial sedation at therapeutic doses, with attendant risks of falls in the night, enuresis, and new onset parasomnias, means that a careful approach to prescribing is needed, especially in patients with compromised respiration in sleep because of, for example, obstructive sleep apnoea. However, it is the only drug available for use in narcolepsy that simultaneously treats all three cardinal symptoms. Since it was licensed in 2006, we, in common with sleep specialists around the world, have found it a remarkably effective treatment. Despite the need for gradual titration and the nuisance of taking the drug twice nightly, many patients find sodium oxybate life transforming, often enabling them to return to work or to study after months or years of enforced absence.
Sodium oxybate is currently priced at around £13 000 (€16 764; $18 929) a year at full dose, although many patients are optimally treated on lower doses. Prescribing policies around the UK are inconsistent. The Department of Health has agreed to underwrite its cost in selected vaccine related cases (a small narcolepsy epidemic followed the use of Pandemrix, a brand of H1N1 flu vaccine, in 2009-10). 5 Some clinical commissioning groups have agreed sensible prescribing arrangements with local hospitals-for example in Cambridgeshire, 6 London, and Merseyside. In most parts of the country, however, use of the drug requires the approval of an individual funding request, showing that a patient's need is "exceptional." 7 8 This process is tortuous, primarily because of the lack of clarity in the definition of exceptionality. Given the drug's cost, together with variations in the severity of narcolepsy and response to standard treatments, prescribing policies that restrict its use to more severely affected patients who respond poorly to other treatment seem sensible. But under the opaque operation of the exceptionality rule, a patient will be allowed sodium oxybate only if his or her response to the drug is judged likely to be exceptional compared with that of a patient with a similar degree of clinical need. This cannot be predicted from the available trial data. In our joint experience of around 30 applications, the increasingly rare agreements to fund the drug are emerging at random. Of 10 recent applications made by the authors in carefully selected patients, none has been successful. Reasons given for refusal have included the explanation that "the patient belongs to a cohort of similar patients." This logically necessary truth provides a convenient but empty justification for declining to fund valuable therapies.
Sodium oxybate is costly, potent, and should be prescribed with care. However, the individual funding request process is time wasting for doctors, frustrating for patients, and fundamentally irrational. It should be abandoned. We suggest that it should be replaced by agreements, like those mentioned above, to fund the drug, under the care of appropriate specialists, for patients 
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who meet predetermined criteria, including more severe disease or failure of, contraindications to, or serious side effects from other treatments. We note that NHS England has recently issued a draft proposal relating to the use of sodium oxybate in postpubertal children 9 along lines similar to these; we welcome this but can see no good reason for adopting different policies towards postpubertal children and adults. We hope that the recent decision to allow a judicial review of prescribing 10 will lead to a more rational and equitable approach to the use of this expensive but valuable drug that is allowing many people with narcolepsy to maintain their personal and social relationships, achieve their academic potential, and remain in employment.
